Evidence map›Paper›PMID 42838957›Full record

ArticleNature communications2026

PRMT7 restricts CD8+ T cells expansion via the NF-ΚB pathway.

Nivine Srour, Kaixiu Luo, David Allard, Yan Xiong, Zhenbao Yu, Theodore Papadopoulos, François Santinon, Cheng-Hsun Hsieh, Anthony Parent, John Stagg and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Nivine Srour *Segal Cancer Center, Lady Davis Institute for Medical Research and Gerald Bronfman Department of Oncology, McGill University, Montréal, QC, Canada.ORCID 0000-0001-5302-9331
Kaixiu Luo *Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Science, Oncological Science and Neuroscience, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
David AllardInstitut du Cancer de Montréal, Centre Hospitalier de l'Université de Montréal (CHUM), Cancer Axis, CHUM Research Center, Montréal, QC, Canada.
Yan XiongMount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Science, Oncological Science and Neuroscience, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-3862-3663
Zhenbao YuSegal Cancer Center, Lady Davis Institute for Medical Research and Gerald Bronfman Department of Oncology, McGill University, Montréal, QC, Canada.
Theodore PapadopoulosSegal Cancer Center, Lady Davis Institute for Medical Research and Gerald Bronfman Department of Oncology, McGill University, Montréal, QC, Canada.ORCID 0009-0005-3004-5298
François SantinonSegal Cancer Center, Lady Davis Institute for Medical Research and Gerald Bronfman Department of Oncology, McGill University, Montréal, QC, Canada.
Cheng-Hsun HsiehSegal Cancer Center, Lady Davis Institute for Medical Research and Gerald Bronfman Department of Oncology, McGill University, Montréal, QC, Canada.
Anthony ParentSegal Cancer Center, Lady Davis Institute for Medical Research and Gerald Bronfman Department of Oncology, McGill University, Montréal, QC, Canada.ORCID 0009-0005-8279-9446
John StaggInstitut du Cancer de Montréal, Centre Hospitalier de l'Université de Montréal (CHUM), Cancer Axis, CHUM Research Center, Montréal, QC, Canada.ORCID 0000-0001-7833-4228
Simon TurcotteDepartement of Surgery, Centre Hospitalier de l'Université de Montréal (CHUM), Cancer Axis, CHUM Research Center, Montréal, QC, Canada.
Dalia Barsyte-LovejoyStructural Genomics Consortium, Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.ORCID 0000-0002-6560-9621
Stéphanie LehouxDepartment of Human Genetics, McGill University, Montréal, QC, Canada.
Sonia V Del RincónSegal Cancer Center, Lady Davis Institute for Medical Research and Gerald Bronfman Department of Oncology, McGill University, Montréal, QC, Canada.
Jian JinMount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Science, Oncological Science and Neuroscience, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. jian.jin@mssm.edu.ORCID 0000-0002-2387-3862
Stéphane RichardSegal Cancer Center, Lady Davis Institute for Medical Research and Gerald Bronfman Department of Oncology, McGill University, Montréal, QC, Canada. stephane.richard@mcgill.ca.ORCID 0000-0003-2665-4806

Funding

Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre (Skin Research Training Centre) PJT-198035
6 · The paper itself

Abstract

Successful cellular immunotherapy for cancer utilising cytotoxic T lymphocytes (CTL) requires efficient expansion while maintaining effector function. Understanding how CTL expansion and function are regulated during the cell preparation process is thus important. Here, we show that T cell-specific deletion of Prmt7 using CD4-Cre increases CD8

Indexed as

CD8-Positive T-LymphocytesNF-kappa BProtein-Arginine N-MethyltransferasesAnimalsAntigens, CDAntigens, Differentiation, T-LymphocyteCell DifferentiationCell Line, TumorCell ProliferationFemaleHumansInterferon-gammaLymphocyte ActivationMiceMice, Inbred C57BLMice, KnockoutAntigens, CDAntigens, Differentiation, T-LymphocyteInterferon-gammaNF-kappa BProtein-Arginine N-MethyltransferasesProteolysis Targeting ChimeraTranscription Factor RelA

Identifiers

PMID42838957
PMCPMC13642902

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.